Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

ABSTRACT:

SUBMITTER: De Smedt R 

PROVIDER: S-EPMC6312037 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature